BI 2536 Second Line Monotherapy in SCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00412880
Recruitment Status : Completed
First Posted : December 19, 2006
Last Update Posted : May 16, 2014
Information provided by:
Boehringer Ingelheim

Brief Summary:
Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.

Condition or disease Intervention/treatment Phase
Carcinoma, Small Cell Drug: BI 2536 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer
Study Start Date : January 2007
Actual Primary Completion Date : June 2008

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Objective tumor response evaluated according to the RECIST criteria by tumor measurements using standard imaging (CT, MRI) [ Time Frame: at least 6 weeks ]

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: at least 6 weeks ]
  2. Overall survival [ Time Frame: at least 6 weeks ]
  3. Duration of overall response [ Time Frame: at least 6 weeks ]
  4. Occurrence and intensity of adverse events graded according to CTCAE [ Time Frame: at least 6 weeks ]
  5. Occurrence of dose limiting toxicity [ Time Frame: at least 6 weeks ]
  6. Number of patients with significant abnormalities in laboratory parameters [ Time Frame: 36 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed, -sensitive-relapse- SCLC defined by a relapse 60 days or more after cessation of prior first-line chemotherapy.
  • Patients with at least one measurable lesion, with longest diameter to be recorded as 20 mm or greater.
  • Life expectancy of at least three months and ECOG performance score of 2 or less and written informed consent that must be consistent with ICH-GCP Guidelines.

Exclusion Criteria:

Exclusion Criteria:

  • More than one prior regimen of chemotherapy, mixed small cell/large cell or combined small cell histology.
  • Symptomatic brain metastases or leptomenigeal disease
  • Patients with ascites, patients who have any other life-threatening illness or organ system dysfunction, or other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer)
  • Absolute neutrophil count (ANC) <1,500/µl, platelet count <100,000/µl, or hemoglobin <9 mg/dl
  • Total bilirubin >1.5 x ULN, aspartame amino transferase (AST) and/or alanine amino transferase (ALT) >2.5 x ULN, or aspartate amino transferase (AST) and/or alanine amino transferase (ALT) >5 x ULN in case of known liver metastases, serum creatinine >2.0 mg/dl (>176 µmol/L, SI Unit equivalent)
  • Chemo-, hormone- (other than Megace®) or immunotherapy within the past 4 weeks or within less than 4 half-life times of the previous drug prior to treatment with the trial drug
  • Radiation therapy within the past 2 weeks prior to or during treatment with the trial drug
  • Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents), patients with known HIV, hepatitis-B or -C infection
  • Known or suspected active drug or alcohol abuse
  • Treatment with any other investigational drug within the past 4 weeks or within less than 4 half-life times of the investigational drug
  • Patients with a known pre-existing coagulopathy or requiring therapeutic anticoagulation with warfarin (Coumadin ®)
  • Patients with neuropathy (sensory or motor) CTCAE 3

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00412880

United States, Arkansas
1216.11.007 Boehringer Ingelheim Investigational Site
Fayetteville, Arkansas, United States
United States, Illinois
1216.11.003 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1216.11.006 Boehringer Ingelheim Investigational Site
Evanston, Illinois, United States
United States, Massachusetts
1216.11.002 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
United States, Missouri
1216.11.005 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, North Carolina
1216.11.001 Boehringer Ingelheim Investigational Site
Chapel Hill, North Carolina, United States
United States, South Carolina
1216.11.011 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1216.11.010 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
United States, Washington
1216.11.012 Boehringer Ingelheim Investigational Site
Seattle, Washington, United States
Canada, Alberta
1216.11.009 Alberta Cancer Board
Edmonton, Alberta, Canada
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00412880     History of Changes
Other Study ID Numbers: 1216.11
First Posted: December 19, 2006    Key Record Dates
Last Update Posted: May 16, 2014
Last Verified: April 2014

Additional relevant MeSH terms:
Carcinoma, Small Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type